OtherPublishAheadOfPrint
Salvage Therapy with 177Lu-Octreotate in Patients with Bronchial and Gastroenteropancreatic Neuroendocrine Tumors
Martijn van Essen, Eric P. Krenning, Boen L.R. Kam, Wouter W. de Herder, Richard A. Feelders and Dik J. Kwekkeboom
Journal of Nuclear Medicine February 2010, DOI: https://doi.org/10.2967/jnumed.109.068957
Martijn van Essen
Eric P. Krenning
Boen L.R. Kam
Wouter W. de Herder
Richard A. Feelders
This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
Journal of Nuclear Medicine
Vol. 65, Issue 4
April 1, 2024
Salvage Therapy with 177Lu-Octreotate in Patients with Bronchial and Gastroenteropancreatic Neuroendocrine Tumors
Martijn van Essen, Eric P. Krenning, Boen L.R. Kam, Wouter W. de Herder, Richard A. Feelders, Dik J. Kwekkeboom
Journal of Nuclear Medicine Feb 2010, DOI: 10.2967/jnumed.109.068957
Jump to section
Related Articles
Cited By...
- Effectiveness and Safety of Retreatment with 177Lu-DOTATATE in Patients with Progressive Neuroendocrine Tumors: A Retrospective Real-World Study in the United States
- Peptide Receptor Radionuclide Therapy of Late-Stage Neuroendocrine Tumor Patients with Multiple Cycles of 177Lu-DOTA-EB-TATE
- GEP-NETS UPDATE: Radionuclide therapy in neuroendocrine tumors
- Targeted Radionuclide Therapy: Proceedings of a Joint Workshop Hosted by the National Cancer Institute and the Society of Nuclear Medicine and Molecular Imaging
- Safety and efficacy of everolimus in gastrointestinal and pancreatic neuroendocrine tumors after 177Lu-octreotate
- Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours
- Response and Long-Term Control of Bone Metastases After Peptide Receptor Radionuclide Therapy with 177Lu-Octreotate
- Therapeutic strategies for advanced neuroendocrine carcinomas of jejunum/ileum and pancreatic origin
- Dynamic and Static Small-Animal SPECT in Rats for Monitoring Renal Function After 177Lu-Labeled Tyr3-Octreotate Radionuclide Therapy